Inside EPA Includes Comments From Richard E. Engler, Ph.D. In Article “Agencies Receive Conflicting Comments On Update Of Biotech Reviews”
On November 6, 2015, Inside EPA included comments made by Richard E. Engler, Ph. D. at a public meeting held by EPA, USDA, and FDA to update the federal coordinated framework for how the three agencies regulate biotechnology.
[…]Industry officials, meanwhile, emphasized biotechnology’s growing importance in food production and cautioned that over-regulation will stifle innovation. Officials with Dupont and the law firm Bergeson & Campbell, P.C., which represents industry clients, called for science-based assessments that consider products’ risks and benefits.
[…]Richard Engler, of Bergeson & Campbell, said more transparent risk-based reviews will improve public understanding of biotechnology. Agencies need adequate funding to ensure adequate and transparent reviews, he said, adding that federal technology centers are needed to facilitate regulators’ understanding of new technologies and facilitate information sharing between agencies. […]